Producer Cuts Alzheimer's Risk With Infusion, Lifestyle

Adults with a family history of Alzheimer's may find this single case useful when discussing biomarker testing and treatment options with their doctor.

Updated on Nov. 2, 2026 in Alzheimer’s

Soft morning light falls across a plain wooden kitchen counter with a glass of water and running shoes on the floor beside it. — Susan Kroll, an NBC News producer, said she cut sweets and alcohol, moved up her bedtime and added regular cardio and strength training after learning of her elevated Alzheimer's risk. AI Illustration. Upload story photo >

NBC News producer Susan Kroll, 58, described on TODAY the steps she took after learning of her elevated genetic risk for Alzheimer's disease, including diet and exercise changes and an anti-amyloid infusion treatment. Her follow-up scan in May showed her amyloid levels had resolved.

Why it matters

Kroll's account shows how people with a family history of Alzheimer's are weighing lifestyle changes alongside newer drug treatments that target amyloid plaque. The story arrives as Kisunla, approved by the FDA in 2024, is becoming part of individual treatment conversations.

This is a single personal case report rather than a controlled study, tracking one patient's amyloid scan score from 86 to 4 after six Kisunla infusions and lifestyle changes. The broader estimate that up to 45% of dementia cases could be delayed or prevented comes from research on modifiable risk factors, and this single case cannot confirm that figure.

The players

Susan Kroll

NBC News producer who shared her personal experience reducing her Alzheimer's risk after genetic and biomarker findings.

Kisunla

An anti-amyloid infusion treatment for Alzheimer's disease approved by the FDA in 2024 that targets amyloid plaque in the brain.

The details

Kroll's mother was diagnosed with Alzheimer's disease, and doctors detected positive biomarkers and elevated amyloid plaque levels in Kroll's brain. Kisunla is an anti-amyloid infusion designed to clear amyloid plaque from the brain. Kroll also cut artificial sweeteners, fried and processed foods, red meat, cheese, sweets and alcohol from her diet, moved up her bedtime, and increased her exercise to 45-60 minutes of cardio three to four days a week plus strength training.

The FDA approved Kisunla for Alzheimer's treatment in 2024.
Kroll's follow-up scan in May 2026 showed her amyloid issue had resolved.
Kroll's story was featured on TODAY on November 2, 2026.

Health Landscape

The 2024 FDA approval of Kisunla added an anti-amyloid infusion option to Alzheimer's care, which had previously relied largely on symptom management. Kroll's account reflects a growing interest in pairing such drugs with modifiable risk reduction for people with elevated genetic risk.

If you have a family history of Alzheimer's, it may be worth raising your genetic and biomarker risk with your doctor and asking whether testing is appropriate for you. Lifestyle factors such as diet, exercise and sleep are areas where personal changes are commonly discussed alongside any medical decisions.

The takeaway

Kroll's experience highlights that people with a family history of Alzheimer's can discuss both biomarker testing and lifestyle changes with their physician. Any decision about infusion treatment should be made in consultation with a clinician.